Skip to main content
SpringerLink
Log in

Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS): The New Thinking

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

TTP and HUS are two disorders with many similarities. Though their first descriptions appeared at different time in history, there has been a trend among physicians to consider them as the same clinical entity. However, in recent years new research findings on the pathophysiology of TTP and HUS have revealed some differences between the two disorders. In this paper, we will review the current approaches to the clinical and laboratory diagnosis of TTP and HUS, as well as therapeutic strategies. We will also summarize the recent advances in three areas in the study of the pathophysiology of TTP and HUS, namely the newly discovered von Willebrand factor multimer-cleaving protease, endothelial cell apoptosis induced by serum from patients with TTP and atypical HUS and the activation of complement system. Since distinguishing and differentiating between TTP and HUS may help to develop more effective therapies targeted at key steps␣of the disease development, we will discuss possible ways of reclassifying the TTP-HUS disorders. In the end, we also present our views on possible future development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McCrae KR, Cines D. Thrombocytopenic purpura and hemolytic uremic syndrome. In Hoffman R, Benz EJ Jr, Shattil SJ, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic principles and practice. 3rd ed. Philadelphia, PA: Churchill Livingstone, 2000: 2126–2138.

    Google Scholar 

  2. Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathology Society 1924;29:21–24.

    Google Scholar 

  3. Baehr G, Klemperer P, Schifrin A. Acute febrile anemia and thrombocytopenic purpura with diffuse platelet thrombosis of capillaries and arterioles. Trans Assoc Am Physicians 1936;51:43–58.

    Google Scholar 

  4. Neame PB. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 1980;6:416–429.

    PubMed  Google Scholar 

  5. Leaf AN, Laubenstein LJ, Raphael B, Hochster H, Baez L, Karpatkin S. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection. Ann Intern Med 1988;109:194–197.

    PubMed  Google Scholar 

  6. Chen DK, Kim JS, Sutton DM. Thrombotic thrombocytopenic purpura associated with Ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 1999;159:311–314.

    Article  PubMed  Google Scholar 

  7. Cuttner J. Thrombotic thrombocytopenic purpura: a ten year experience. Blood 1980;56:302–306.

    PubMed  Google Scholar 

  8. Weiner CP. Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 1987;24:119–129.

    PubMed  Google Scholar 

  9. Dekker A, O'Brien ME, Cammarata RJ. The association of thrombotic thrombocytopenic purpura with systemic lupus erythematosus: a report of two cases with successful treatment of one. Am J Med Sci 1974;267:243–249.

    PubMed  Google Scholar 

  10. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987;24:161–177.

    PubMed  Google Scholar 

  11. Van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated thrombotic thrombocytopenic purpura. Blood 1999;93:3798–3802.

    PubMed  Google Scholar 

  12. Amorosi EL, Ulmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966;45:139–159.

    Google Scholar 

  13. Gasser C, Gautier C, Steck A, et al. Hämolytischurämische syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wchnschr 1955;85:905–909.

    Google Scholar 

  14. Kaplan BS. Recalling Barnard and Kibel's hypothesis on hemolytic uremic syndrome. Pediatr Nephrol 1999;13:466–467.

    Article  PubMed  Google Scholar 

  15. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983;1:619–620.

    Article  PubMed  Google Scholar 

  16. Bitzan M, Moebius E, Ludwig K, Müller-Wiefel DE, Heesemann J, Karch H. High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic uremic syndrome. J Pediatr 1991;119:380–385.

    PubMed  Google Scholar 

  17. Louise CB, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 1992;60:1536–1543.

    PubMed  Google Scholar 

  18. Tesh VL, Samuel JE, Perera LP, Sharefkin JB, O'Brien AD. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis 1991;164:344–352.

    PubMed  Google Scholar 

  19. Van der Kar NCA, Monnens LAH, Karmali MA, van Hinsbergh VWM. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992;80:2755–2764.

    PubMed  Google Scholar 

  20. Barnard PJ, Kibel M. The hemolytic uremic syndrome of infancy and childhood. A report of eleven cases. Cent Afr J Med 1965;11:4-11;11:31–34.

    Google Scholar 

  21. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1995;47:2–19.

    Google Scholar 

  22. Furlan M. Von Willebrand Factor: molecular size and functional activity. Ann Hematol 1996;72:341–348.

    Article  PubMed  Google Scholar 

  23. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990;87:6306–6310.

    PubMed  Google Scholar 

  24. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Eng J Med 1982;307:1432–1435.

    Google Scholar 

  25. Moake JL, Byrnes JJ, Troll JH, et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985;65:1232–1236.

    PubMed  Google Scholar 

  26. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223–4234.

    PubMed  Google Scholar 

  27. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235–4244.

    PubMed  Google Scholar 

  28. Moake JL. Moschcowitz, multimers, and metalloprotease. N Eng J Med 1998;339:1629–1631.

    Article  Google Scholar 

  29. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Eng J Med 1998;339:1578–1584.

    Article  Google Scholar 

  30. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Eng J Med 1998;339:1585–1594.

    Article  Google Scholar 

  31. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839–2846.

    PubMed  Google Scholar 

  32. Mannucci PM. Thrombotic thrombocytopenic purpura: a simpler diagnosis at last. Thromb Haemost 1999;82:1380–1381.

    PubMed  Google Scholar 

  33. Sarkodee-Adoo C, Gojo I, Heyman MR. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome (correspondence). N Eng J Med 1999; 340:1368.

    Google Scholar 

  34. Furlan M, Lämmle M. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome (correspondence). N Eng J Med 1999;340:1369.

    Article  Google Scholar 

  35. Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun 1977;18:775–779.

    PubMed  Google Scholar 

  36. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985;151:775–782.

    PubMed  Google Scholar 

  37. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol 1996;4:147–153.

    Article  PubMed  Google Scholar 

  38. Perna NT, Plunkett G III, Burland V, et al. Genome sequence of enterohaemorrhagic Escherichia Coli O157:H7. Nature 2001;409:529–533.

    Article  PubMed  Google Scholar 

  39. Decludt B, Bouvet P, Mariani-Kurkdjian P, et al. Hemolytic uremic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Societe de Nephrologie Pediatrique. Epidemiol Infect 2000;124:215–220.

    Article  PubMed  Google Scholar 

  40. Verweyen HM, Karch H, Allerberger F, Zimmerhackl LB. Enterohemorrhagic Escherichia coli (EHEC) in pediatric hemolytic-uremic syndrome: a prospective study in Germany and Austria. Infection 1999;27: 341–347.

    Article  PubMed  Google Scholar 

  41. O'Ryan M, Prado V. Risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections (correspondence). N Eng J Med 2000;343:1271.

    Article  Google Scholar 

  42. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993;268:15484–15488.

    PubMed  Google Scholar 

  43. Te Leo DMWM, Monnens LAH, van der Velden TJAM, et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000;95:3396–3402.

    PubMed  Google Scholar 

  44. Warwicker P, Goodship THJ, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836–844.

    Article  PubMed  Google Scholar 

  45. Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of βH globulin. Clin Exp Immunol 1981;46:110–119.

    PubMed  Google Scholar 

  46. Roodhooft AM, McLean RH, Elst E, Van Acker KJ. Recurrent hemolytic uremic syndrome and acquired hypomorphic variant of the third component of complement. Pediatr Nephrol 1990;4:597–599.

    PubMed  Google Scholar 

  47. Pinchette V, Quérin S, Schü rch W, Brun G, Lehner-Netsch G, Delâge JM. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994;24:936–941.

    PubMed  Google Scholar 

  48. Noris M, Remuzzi G. Are HUS and TTP genetically determined? Kidney Int 1998;53:1085–1086.

    PubMed  Google Scholar 

  49. Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996;87:3245–3254.

    PubMed  Google Scholar 

  50. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224–1234.

    PubMed  Google Scholar 

  51. Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood 1999;93:1264–1270.

    PubMed  Google Scholar 

  52. Laurence J, Mitra D. Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. Semin Hematol 1997;34:98–105.

    PubMed  Google Scholar 

  53. Nevard CH, Blann AD, Jurd KM, Haycock GB, Hunt BJ. Markers of endothelial cell activation and injury in childhood hemolytic uremic syndrome. Pediatr Nephrol 1999;13:487–492.

    Article  PubMed  Google Scholar 

  54. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine-Thrombotic Thrombocytopenic Purpura (TTP) 271 a review of 60 cases. Ann Intern Med 1998;128: 541–544.

    PubMed  Google Scholar 

  55. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Eng J Med 2000;342:1773–1777.

    Article  Google Scholar 

  56. Moy B, Wang JC, Raffel GD, Marcoux JP. Hemolytic uremic syndrome associated with clopidogrel. Arch Intern Med 2000;160:1370–1372.

    Article  PubMed  Google Scholar 

  57. Mauro M, Dang C, Raife T, Laurence J. Ticlopidinelinked thrombotic thrombocytopenic purpura: association with endothelial cell apoptosis and disruption of extracellular matrix in vitro and in vivo. Blood 1999;94 (supp. 1, part 1 of 2):646a.

    Google Scholar 

  58. Furlan M. Von Willebrand factor proteolysis in thrombotic thrombocytopenic purpura (correspondence). Blood 1999;94:3611–3612.

    PubMed  Google Scholar 

  59. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223–1239.

    PubMed  Google Scholar 

  60. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF. Thromb Haemost 1999;82:1386–1389.

    PubMed  Google Scholar 

  61. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factorcleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999;82:1382–1385.

    PubMed  Google Scholar 

  62. Siegler RL, Pavia AT, Hansen FL, Christofferson RD, Cook JB. Atypical hemolytic-uremic syndrome: a comparison with postdiarrheal disease. J Pediatr 1996;128:505–511.

    PubMed  Google Scholar 

  63. Zimmerhackl LB. E coli, antibiotics, and the hemolyticuremic syndrome. N Eng J Med 2000;342:1990–1991.

    Article  Google Scholar 

  64. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Eng J Med 2000;342:1930–1936.

    Article  Google Scholar 

  65. Rubenstein MA, Kagan BM, MacGillviray MH, et al. Unusual remission in a case of thrombotic thrombocytopenic purpura syndromefollowing fresh blood exchange transfusions. Ann Intern Med 1959;1409–1419.

  66. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Eng J Med 1991;325:393–397.

    Google Scholar 

  67. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic-hemolytic uremic syndrome: clinical experience in 108 patients. N Eng J Med 1991;325:398–403.

    Google Scholar 

  68. Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992;32:710–714.

    Article  PubMed  Google Scholar 

  69. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WTA. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999;354:1327–1330.

    Article  PubMed  Google Scholar 

  70. Friedberg CK, Gross L. Nonbacterial thrombotic endocarditis associated with acute thrombocytopenic purpura. Arch Intern Med 1936;58:641–661.

    Google Scholar 

  71. Gardner FH, McElfresh AE, Harris JW, et al. The effect of adrenocorticotrophic hormone (ACTH) in idiopathic acquired hemolytic anemia as related to the hemolytic mechanisms. J Lab Clin Med 1951;37: 444–457.

    PubMed  Google Scholar 

  72. Meacham GC, Orbison JL, Heinle RW, et al. Thrombotic thrombocytopenic purpura: disseminated diseases of arterioles. Blood 1951;6:706–719.

    PubMed  Google Scholar 

  73. Bernard RP, Bauman AW, Schwartz SI. Splenectomy for thrombotic thrombocytopenic purpura. Ann Surg 1969;169:616–624.

    PubMed  Google Scholar 

  74. Gillis S. The thrombotic thrombocytopenic purpuras, recognition and management. Drugs 1996;51:942–953.

    PubMed  Google Scholar 

  75. Schreeder MT, Prchal JT. Successful treatment of thrombotic thrombocytopenic purpura by vincristine. Am J Hematol 1983;14:75–78.

    PubMed  Google Scholar 

  76. Finn NG, Wang JC, Hong KJ. High-dose intravenous gamma-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura. Arch Intern Med 1987;147:2165–2167.

    Article  PubMed  Google Scholar 

  77. Bachman WR, Brennan JK. Refractory thrombotic thrombocytopenic purpura treated with cyclosporine. Am J Hematol 1996;51:93–94.

    Article  PubMed  Google Scholar 

  78. Bird JM, Cummins D, Machin SJ. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet 1990;336:565–566.

    Article  Google Scholar 

  79. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian cooperative group for TTP. Haematologica 1997;82:429–435.

    PubMed  Google Scholar 

  80. Laurence J. Pathological and therapeutic distinctions in HUS/TTP. Lancet 2000;355:497.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology (1), From the University of Massachusetts Memorial Health Care, USA

    Jingxuan Liu, Michael Hutzler, Cuizhen Li & Liberto Pechet

Authors
  1. Jingxuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Hutzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cuizhen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liberto Pechet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J., Hutzler, M., Li, C. et al. Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS): The New Thinking. J Thromb Thrombolysis 11, 261–272 (2001). https://doi.org/10.1023/A:1011921122595

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011921122595

Search

Navigation